GlaxoSmithKline plc (the 'Company')
Transaction notification
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||||
a) |
Name |
Ms E Walmsley |
||||||
b) |
Position/status |
Chief Executive Officer |
||||||
c) |
Initial notification/ amendment |
Initial notification |
||||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|||||||
a) |
Name |
GlaxoSmithKline plc |
||||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
|||||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
||||||
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan. |
||||||
c) |
Price(s) and volume(s) |
|
||||||
d) |
Aggregated information
Aggregated volume Price |
20 Ordinary Shares £13.4317
|
||||||
e) |
Date of the transaction |
2018-03-09 |
||||||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||||
a) |
Name |
Mr R G Connor |
||||||
b) |
Position/status |
President, Global Manufacturing & Supply |
||||||
c) |
Initial notification/ amendment |
Initial notification |
||||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|||||||
a) |
Name |
GlaxoSmithKline plc |
||||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
|||||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
||||||
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan. |
||||||
c) |
Price(s) and volume(s) |
|
||||||
d) |
Aggregated information
Aggregated volume Price |
20 Ordinary Shares £13.4317
|
||||||
e) |
Date of the transaction |
2018-03-09 |
||||||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||||
a) |
Name |
Mr S Dingemans |
||||||
b) |
Position/status |
Chief Financial Officer |
||||||
c) |
Initial notification/ amendment |
Initial notification |
||||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|||||||
a) |
Name |
GlaxoSmithKline plc |
||||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
|||||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
||||||
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan. |
||||||
c) |
Price(s) and volume(s) |
|
||||||
d) |
Aggregated information
Aggregated volume Price |
20 Ordinary Shares £13.4317
|
||||||
e) |
Date of the transaction |
2018-03-09 |
||||||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||||
a) |
Name |
Mr N Hirons |
||||||
b) |
Position/status |
SVP, Global Ethics & Compliance |
||||||
c) |
Initial notification/ amendment |
Initial notification |
||||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|||||||
a) |
Name |
GlaxoSmithKline plc |
||||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
|||||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
||||||
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan. |
||||||
c) |
Price(s) and volume(s) |
|
||||||
d) |
Aggregated information
Aggregated volume Price |
20 Ordinary Shares £13.4317
|
||||||
e) |
Date of the transaction |
2018-03-09 |
||||||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||||
a) |
Name |
Mr L Miels |
||||||
b) |
Position/status |
President, Global Pharmaceuticals |
||||||
c) |
Initial notification/ amendment |
Initial notification |
||||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|||||||
a) |
Name |
GlaxoSmithKline plc |
||||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
|||||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
||||||
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan. |
||||||
c) |
Price(s) and volume(s) |
|
||||||
d) |
Aggregated information
Aggregated volume Price |
20 Ordinary Shares £13.4317
|
||||||
e) |
Date of the transaction |
2018-03-09 |
||||||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||||
a) |
Name |
Mr D S Redfern |
||||||
b) |
Position/status |
Chief Strategy Officer |
||||||
c) |
Initial notification/ amendment |
Initial notification |
||||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|||||||
a) |
Name |
GlaxoSmithKline plc |
||||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
|||||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
||||||
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan. |
||||||
c) |
Price(s) and volume(s) |
|
||||||
d) |
Aggregated information
Aggregated volume Price |
20 Ordinary Shares £13.4317
|
||||||
e) |
Date of the transaction |
2018-03-09 |
||||||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||||
a) |
Name |
Ms C Thomas |
||||||
b) |
Position/status |
SVP, Human Resources |
||||||
c) |
Initial notification/ amendment |
Initial notification |
||||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|||||||
a) |
Name |
GlaxoSmithKline plc |
||||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
|||||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
||||||
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan. |
||||||
c) |
Price(s) and volume(s) |
|
||||||
d) |
Aggregated information
Aggregated volume Price |
20 Ordinary Shares £13.4317
|
||||||
e) |
Date of the transaction |
2018-03-09 |
||||||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||||
a) |
Name |
Mr P C Thomson |
||||||
b) |
Position/status |
President, Global Affairs |
||||||
c) |
Initial notification/ amendment |
Initial notification |
||||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|||||||
a) |
Name |
GlaxoSmithKline plc |
||||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
|||||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
||||||
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan. |
||||||
c) |
Price(s) and volume(s) |
|
||||||
d) |
Aggregated information
Aggregated volume Price |
18 Ordinary Shares £13.4317
|
||||||
e) |
Date of the transaction |
2018-03-09 |
||||||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||||
a) |
Name |
Dr P J T Vallance |
||||||
b) |
Position/status |
President, R&D |
||||||
c) |
Initial notification/ amendment |
Initial notification |
||||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|||||||
a) |
Name |
GlaxoSmithKline plc |
||||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
|||||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
||||||
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan. |
||||||
c) |
Price(s) and volume(s) |
|
||||||
d) |
Aggregated information
Aggregated volume Price |
18 Ordinary Shares £13.4317
|
||||||
e) |
Date of the transaction |
2018-03-09 |
||||||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||||
a) |
Name |
Mrs V A Whyte |
||||||
b) |
Position/status |
Company Secretary |
||||||
c) |
Initial notification/ amendment |
Initial notification |
||||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|||||||
a) |
Name |
GlaxoSmithKline plc |
||||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
|||||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
||||||
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan. |
||||||
c) |
Price(s) and volume(s) |
|
||||||
d) |
Aggregated information
Aggregated volume Price |
20 Ordinary Shares £13.4317
|
||||||
e) |
Date of the transaction |
2018-03-09 |
||||||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |